You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Merck
McKinsey
Moodys
AstraZeneca

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,906,489

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,906,489 protect, and when does it expire?

Patent 7,906,489 protects DIFICID and is included in two NDAs.

Protection for DIFICID has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and twenty-two patent family members in twenty-eight countries.

Summary for Patent: 7,906,489
Title:18-membered macrocycles and analogs thereof
Abstract: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.
Inventor(s): Shue; Youe-Kong (Carlsbad, CA), Hwang; Chan-Kou (San Diego, CA), Chiu; Yu-Hung (San Diego, CA), Romero; Alex (San Diego, CA), Babakhani; Farah (San Diego, CA), Sears; Pamela (San Diego, CA), Okumu; Franklin (Oakland, CA)
Assignee: Optimer Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/882,219
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,906,489
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,906,489

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc DIFICID fidaxomicin FOR SUSPENSION;ORAL 213138-001 Jan 24, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cubist Pharms Llc DIFICID fidaxomicin TABLET;ORAL 201699-001 May 27, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,906,489

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 516024   Start Trial
Australia 2003251902   Start Trial
Australia 2005327308   Start Trial
Australia 2006304868   Start Trial
Australia 2008209580   Start Trial
Brazil PI0511119   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
AstraZeneca
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.